Analyst Expectations for Mind Medicine's Future
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 8 analysts have published their opinion on Mind Medicine (NASDAQ:MNMD) stock. The average price target is $27.0, a 32.5% decrease from the previous average price target of $40.00. The analysts' ratings are evenly split between bullish and somewhat bullish.
August 22, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Analysts have given Mind Medicine a mixed rating, with an average price target of $27.0, down 32.5% from the previous target.
The mixed analyst ratings indicate uncertainty about the company's future performance. The decrease in the average price target suggests that analysts have lowered their expectations for the stock, which could potentially impact its price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100